These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19946587)

  • 21. Pharmacogenomic biomarkers do not predict response to drotrecogin alfa in patients with severe sepsis.
    Annane D; Mira JP; Ware LB; Gordon AC; Hinds CJ; Christiani DC; Sevransky J; Barnes K; Buchman TG; Heagerty PJ; Balshaw R; Lesnikova N; de Nobrega K; Wellman HF; Neira M; Mancini ADJ; Walley KR; Russell JA
    Ann Intensive Care; 2018 Jan; 8(1):16. PubMed ID: 29388048
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical impact of stress dose steroids in patients with septic shock: insights from the PROWESS-Shock trial.
    Póvoa P; Salluh JI; Martinez ML; Guillamat-Prats R; Gallup D; Al-Khalidi HR; Thompson BT; Ranieri VM; Artigas A
    Crit Care; 2015 Apr; 19(1):193. PubMed ID: 25928214
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drotrecogin alfa (activated) in adults with septic shock.
    Ranieri VM; Thompson BT; Barie PS; Dhainaut JF; Douglas IS; Finfer S; Gårdlund B; Marshall JC; Rhodes A; Artigas A; Payen D; Tenhunen J; Al-Khalidi HR; Thompson V; Janes J; Macias WL; Vangerow B; Williams MD;
    N Engl J Med; 2012 May; 366(22):2055-64. PubMed ID: 22616830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. From bench to bedside: a review of the clinical trial development plan of drotrecogin alfa (activated).
    Short MA; Schlichting D; Qualy RL
    Curr Med Res Opin; 2006 Dec; 22(12):2525-40. PubMed ID: 17265595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current role of activated protein C therapy for severe sepsis and septic shock.
    Barie PS
    Curr Infect Dis Rep; 2008 Sep; 10(5):368-76. PubMed ID: 18687200
    [TBL] [Abstract][Full Text] [Related]  

  • 26. International INtegrated Database for the Evaluation of severe sePsis and drotrecogin alfa (activated) THerapy: component trials and statistical methods for INDEPTH.
    Sashegyi A; Trzaskoma BL; Nelson DR; Williams MD; Macias W
    Curr Med Res Opin; 2006 May; 22(5):1001-12. PubMed ID: 16709322
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A dream deferred: the rise and fall of recombinant activated protein C.
    Holder AL; Huang DT
    Crit Care; 2013 Mar; 17(2):309. PubMed ID: 23509922
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of drotrecogin alfa (activated) in severe sepsis: data from adult clinical trials and observational studies.
    Woodward B; Cartwright M
    J Crit Care; 2009 Dec; 24(4):595-602. PubMed ID: 19327331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Near-infrared spectroscopy StO2 monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock.
    Masip J; Mesquida J; Luengo C; Gili G; Gomà G; Ferrer R; Teboul JL; Payen D; Artigas A
    Ann Intensive Care; 2013 Sep; 3(1):30. PubMed ID: 24007807
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of drotrecogin alfa (activated) on long-term survival after severe sepsis.
    Angus DC; Laterre PF; Helterbrand J; Ely EW; Ball DE; Garg R; Weissfeld LA; Bernard GR;
    Crit Care Med; 2004 Nov; 32(11):2199-206. PubMed ID: 15640631
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study.
    Laterre PF; Garber G; Levy H; Wunderink R; Kinasewitz GT; Sollet JP; Maki DG; Bates B; Yan SC; Dhainaut JF;
    Crit Care Med; 2005 May; 33(5):952-61. PubMed ID: 15891319
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs.
    Ernst FR; Johnston JA; Pulgar S; He J; Ball DE; Young JK; Cooper LM
    Curr Med Res Opin; 2007 Jan; 23(1):235-44. PubMed ID: 17207305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulant properties of drotrecogin alfa (activated) during hemofiltration in patients with severe sepsis.
    de Pont AC; Schultz MJ
    Crit Care; 2009; 13(1):113. PubMed ID: 19226446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PROWESS, ENHANCE and ADDRESS: clinical implications for the treatment with drotrecogin alfa (activated)].
    Cobas Meyer M; Langenfeld H; Rossaint R; Sablotzki A
    Anaesthesist; 2006 Jun; 55 Suppl 1():16-23. PubMed ID: 16680442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The safety profile of drotrecogin alfa (activated).
    Fumagalli R; Mignini MA
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S6. PubMed ID: 18269693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive safety analysis of concomitant drotrecogin alfa (activated) and prophylactic heparin use in patients with severe sepsis.
    Levy M; Levi M; Williams MD; Antonelli M; Wang D; Mignini MA
    Intensive Care Med; 2009 Jul; 35(7):1196-203. PubMed ID: 19367397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The protein C pathway: implications for the design of the RESPOND study.
    Vangerow B; Shorr AF; Wyncoll D; Janes J; Nelson DR; Reinhart K
    Crit Care; 2007; 11 Suppl 5(Suppl 5):S4. PubMed ID: 18269691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: 28-day survival and safety.
    Laterre PF; Nelson DR; Macias W; Abraham E; Sashegyi A; Williams MD; Levy M; Levi M; Utterback B; Vincent JL
    J Crit Care; 2007 Jun; 22(2):142-52. PubMed ID: 17548026
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early drotrecogin alpha (activated) administration in severe sepsis is associated with lower mortality: a retrospective analysis of the Canadian ENHANCE cohort.
    Hodder RV; Hall R; Russell JA; Fisher HN; Lee B
    Crit Care; 2009; 13(3):R78. PubMed ID: 19457240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis.
    Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP
    Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.